Jamie Dlugosch

Jamie Dlugosch

InvestorPlace Writer

Jamie Dlugosch has over 20 years of experience in financial markets including investment banking, equity analysis and research and money management.

Previously, he was the publisher of Al Frank’s Prudent Speculator and CEO of Al Frank Investment Management Inc. He is the founder and editor of The Rational Investor.

Jamie earned his Master’s in Business Administration from the University of North Carolina. He currently lives in Minneapolis with his wife, Sarah, and their two daughters, Julia and Ellie.

Recent Articles

Whirlpool Corp. (WHR): Better Days Ahead?

By Jamie Dlugosch, InvestorPlace Writer

After two years of decimation in the homebuilding sector is Whirlpool (WHR) now worthy of investment consideration?

Weekly Credit Market Report

By Jamie Dlugosch, InvestorPlace Writer

Economic reports released this past week is further evidence that the economy continues in its recessionary mode.

Akamai (AKAM) Performs Beyond Expectations

By Jamie Dlugosch, InvestorPlace Writer

Shares of Akamai Technologies Inc. (AKAM) surged 18 percent higher on Thursday after the company's fourth quarter earnings report beat Wall Street's expectations.

Investors Take Profits on Dollar Tree

By Jamie Dlugosch, InvestorPlace Writer

Apparently investors believe that now is the time to get out of their positions in Dollar Tree, Inc. (DLTR). How else does one explain the…

Show Me the Money: 5 Top Investing Ideas

By Jamie Dlugosch, InvestorPlace Writer

Many investors have simply given up on the markets in light of the huge losses during the last year or so. But for those brave souls who are persevering, now is the time for opportunity. And the Money Show is a great place to find ideas that can propel your portfolio forward during difficult times. Here are some of the best ideas from this month's show.

Is OSI Pharmaceuticals (OSIP) a Hit or Miss?

By Jamie Dlugosch, InvestorPlace Writer

Shares of biotech drug firm OSI Pharmaceuticals (OSIP) soared 16 percent higher on Tuesday after a late stage trial found that its cancer pill, Tarceva, when combined with Genentech's Avastin, extended the time patients with advanced lung cancer lived without the disease getting worse.

Corporate Bonds: A Case for Williams Companies (WMB)

By Jamie Dlugosch, InvestorPlace Writer

A close look at Williams Companies (WMB) offers a case study of why an investor should have corporate bonds in their portfolio.

Rockwell (ROK) Hit Hard as Demand Deteriorates

By Jamie Dlugosch, InvestorPlace Writer

When things go bad for the manufacturing industry, they get even worse for their material vendors and their equipment suppliers.

A Game of Survival For Macy’s (M)

By Jamie Dlugosch, InvestorPlace Writer

On Monday Macy's (M) announced that it was taking immediate steps to preserve cash during the current crisis. The company slashed its dividend to $0.05 per share and announced 7,000 job cuts causing shares to fall by more than $1 in the immediate aftermath of the news.

Not Recession-Proof. Hitachi (HIT) Posts $4.1B Loss

By Jamie Dlugosch, InvestorPlace Writer

Once considered recession-proof due to its presence in a wide range of products, Hitachi (HIT), Japan's largest electronics manufacturing concern, has joined the ranks of companies facing massive restructuring needs as the global economy contracts.

Load More